SCHEMBL3197535

SCHEMBL3197535

CC(Oc1ccccc1)C(=O)C1CC2C=CC1C2

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 3/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
NPC1 O15118 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201849 0.75 ALDH1A1 (0.51) ALDH1A1KMT2ATSHRKDM4ELMNA
SCHEMBL21895375 0.73 KDM4E (0.53) ALDH1A1KMT2AGAAKDM4ELMNA
SCHEMBL3197540 0.70 KDM4E (0.45) ALDH1A1KMT2ACYP1A2CYP2C9PKM
Toluene SCHEMBL27618261 0.70 KDM4E (0.46) ALDH1A1KMT2APKMTSHRKDM4E
SCHEMBL31540359 0.69 CYP1A2 (0.75) KMT2ACYP1A2GAACYP2C9PKM
SCHEMBL11582365 0.69 ALDH1A1 (0.52) ALDH1A1KMT2APKMTSHRKDM4E
SCHEMBL14449130 0.69 KDM4E (0.49) ALDH1A1KMT2AKDM4ELMNARAB9A
SCHEMBL818204 0.69 KDM4E (0.49) ALDH1A1KMT2AKDM4ELMNARAB9A
SCHEMBL32688583 0.69 ALDH1A1 (0.59) ALDH1A1KMT2AGAATSHRKDM4E
SCHEMBL7715902 0.69 KDM4E (0.52) ALDH1A1KMT2AGAAKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7675587-B2 Polarizing plate and process for producing the same JSR CORPORATION (JP) 2010-03-09 US disclosed
US-20090176950-A1 METAL HYDRIDE COMPLEX, METHOD OF HYDROGENATING RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN, AND PROCESS FOR PRODUCING PRODUCT OF HYDROGENATION OF RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN JSR CORPORATION (JP) 2009-07-09 US disclosed
EP-1983023-A1 Radiation-curable composition, composite and manufacturing method thereof JSR Corporation (JP) 2008-10-22 EP disclosed
EP-1626294-A2 Polarizing plate and process for producing the same JSR Corporation (JP) 2006-02-15 EP disclosed
US-20060027322-A1 Polarizing plate and process for producing the same JSR CORPORATION (JP) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176950-A1 METAL HYDRIDE COMPLEX, METHOD OF HYDROGENATING RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN, AND PROCESS FOR PRODUCING PRODUCT OF HYDROGENATION OF RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN HPD, HMOX2, HAO2 ALDH1A1 2201/4885KMT2A 3197/4885CYP1A2 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.